Qternmet Xr is a drug owned by Astrazeneca Ab. It is protected by 15 US drug patents filed from 2019 to 2024. Out of these, 11 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 12, 2031. Details of Qternmet Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(4 years from now) | Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(4 months from now) | Active |
| USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(1 year, 9 months ago) |
Expired
|
| US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US9616028 (Pediatric) | Bilayer tablet formulations |
May, 2031
(6 years from now) | Active |
| US9616028 | Bilayer tablet formulations |
Nov, 2030
(5 years from now) | Active |
|
US7919598 (Pediatric) | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2030
(5 years from now) | Active |
|
US8716251 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | Active |
| US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(2 years from now) | Active |
|
US8501698 (Pediatric) | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(2 years from now) | Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(2 years from now) | Active |
|
US6515117 (Pediatric) | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(10 months from now) | Active |
| US8628799 | Coated tablet formulation and method |
Jul, 2025
(2 months from now) | Active |
| US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(4 years ago) |
Expired
|
| US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Qternmet Xr's patents.
Latest Legal Activities on Qternmet Xr's Patents
Given below is the list of recent legal activities going on the following patents of Qternmet Xr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Sep, 2020 | US9616028 |
| Recordation of Patent Grant Mailed Critical | 11 Apr, 2017 | US9616028 |
| Patent Issue Date Used in PTA Calculation Critical | 11 Apr, 2017 | US9616028 |
| Email Notification Critical | 23 Mar, 2017 | US9616028 |
| Issue Notification Mailed Critical | 22 Mar, 2017 | US9616028 |
| Dispatch to FDC | 02 Mar, 2017 | US9616028 |
| Application Is Considered Ready for Issue Critical | 02 Mar, 2017 | US9616028 |
| Issue Fee Payment Verified Critical | 24 Feb, 2017 | US9616028 |
| Issue Fee Payment Received Critical | 24 Feb, 2017 | US9616028 |
| Electronic Review Critical | 28 Nov, 2016 | US9616028 |
FDA has granted several exclusivities to Qternmet Xr. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Qternmet Xr, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Qternmet Xr.
Exclusivity Information
Qternmet Xr holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Qternmet Xr's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 02, 2022 |
Several oppositions have been filed on Qternmet Xr's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Qternmet Xr's generic, the next section provides detailed information on ongoing and past EP oppositions related to Qternmet Xr patents.
Qternmet Xr's Oppositions Filed in EPO
Qternmet Xr has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 30, 2015, by Lek Pharmaceuticals D.D.. This opposition was filed on patent number EP07784499A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08732695A | Dec, 2020 | Stada-Arzneimittel Aktiengesellschaft | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Kraus & Weisert Patentanwälte PartGmbB | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Gedeon Richter Plc. | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Generics [UK] Limited | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Zentiva, k.s. | Granted and Under Opposition |
| EP17203302A | Aug, 2020 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP10782113A | Apr, 2019 | Hoefer & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP15181545A | Sep, 2018 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP10179007A | Mar, 2017 | Galenicum Health S.L. | Patent maintained as amended |
| EP05756474A | Jan, 2017 | Galenicum Health S.L. | Patent maintained as amended |
| EP07784499A | Apr, 2015 | LEK Pharmaceuticals d.d. | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Qternmet Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qternmet Xr's family patents as well as insights into ongoing legal events on those patents.
Qternmet Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Qternmet Xr's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 12, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Qternmet Xr Generics:
There are no approved generic versions for Qternmet Xr as of now.
Alternative Brands for Qternmet Xr
Qternmet Xr which is used for managing blood sugar levels in individuals with type 2 diabetes mellitus., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab |
| |||||||
| Boehringer Ingelheim |
| |||||||
| Cosette |
| |||||||
| Janssen Pharms |
| |||||||
| Sb Pharmco |
| |||||||
About Qternmet Xr
Qternmet Xr is a drug owned by Astrazeneca Ab. It is used for managing blood sugar levels in individuals with type 2 diabetes mellitus. Qternmet Xr uses Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride as an active ingredient. Qternmet Xr was launched by Astrazeneca Ab in 2019.
Approval Date:
Qternmet Xr was approved by FDA for market use on 02 May, 2019.
Active Ingredient:
Qternmet Xr uses Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride ingredient
Treatment:
Qternmet Xr is used for managing blood sugar levels in individuals with type 2 diabetes mellitus.
Dosage:
Qternmet Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG;1GM;EQ 5MG BASE | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 2.5MG;1GM;EQ 2.5MG BASE | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 5MG;1GM;EQ 2.5MG BASE | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 5MG;1GM;EQ 5MG BASE | TABLET, EXTENDED RELEASE | Discontinued | ORAL |